866 related articles for article (PubMed ID: 15041117)
21. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
23. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
[TBL] [Abstract][Full Text] [Related]
24. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
Patki PS; Hamid R; Arumugam K; Shah PJ; Craggs M
BJU Int; 2006 Jul; 98(1):77-82. PubMed ID: 16831148
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH
Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519
[TBL] [Abstract][Full Text] [Related]
27. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
Rajkumar GN; Small DR; Mustafa AW; Conn G
BJU Int; 2005 Oct; 96(6):848-52. PubMed ID: 16153215
[TBL] [Abstract][Full Text] [Related]
28. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
Kuo HC
Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
[TBL] [Abstract][Full Text] [Related]
29. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
[TBL] [Abstract][Full Text] [Related]
30. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
[TBL] [Abstract][Full Text] [Related]
31. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years.
Stoehrer M; Wolff A; Kramer G; Steiner R; Lmöchner-Ernst D; Leuth D; Steude U; Ruebben H
Urol Int; 2009; 83(4):379-85. PubMed ID: 19996642
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
Bagi P; Biering-Sørensen F
Scand J Urol Nephrol; 2004; 38(6):495-8. PubMed ID: 15841785
[TBL] [Abstract][Full Text] [Related]
33. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
35. [Minimally invasive, safe treatment of the neurogenic bladder with botulinum-A-toxin in children with myelomeningocele].
Lusuardi L; Nader A; Koen M; Schrey A; Schindler M; Riccabona M
Aktuelle Urol; 2004 Feb; 35(1):49-53. PubMed ID: 14997415
[TBL] [Abstract][Full Text] [Related]
36. Experience with injections of botulinum toxin type A into the detrusor muscle.
Miyagawa I; Watanabe T; Isoyama T; Honda M; Kobayasi N; Hikita K; Saito M; Hirakawa S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S24-6. PubMed ID: 20094947
[TBL] [Abstract][Full Text] [Related]
37. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor.
Hoebeke P; De Caestecker K; Vande Walle J; Dehoorne J; Raes A; Verleyen P; Van Laecke E
J Urol; 2006 Jul; 176(1):328-30; discussion 330-1. PubMed ID: 16753434
[TBL] [Abstract][Full Text] [Related]
38. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
Mascarenhas F; Cocuzza M; Gomes CM; Leão N
Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
[TBL] [Abstract][Full Text] [Related]
39. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
Grosse J; Kramer G; Stöhrer M
Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
[TBL] [Abstract][Full Text] [Related]
40. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
